Workshop report: Towards a cure: HIV reservoirs and strategies to control them

Journal of the International AIDS Society

Volumn 13, Issue SUPPL. 3, 2010, Pages

  Jefferys, Richard J ^a  

^a Treatment Action Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AURANOFIN; BETA7 INTEGRIN; GAR 1041; HISTONE DEACETYLASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MARAVIROC; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE C INHIBITOR; PROTEIN P21; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ASTROCYTE; BRAIN; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; DISEASE SEVERITY; DNA METHYLATION; DNA TRANSCRIPTION; ENCEPHALITIS; ERADICATION THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HIV ASSOCIATED ENCEPHALITIS; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION CONTROL; INFLAMMATION; INTESTINE; LIFE EXPECTANCY; MYELOID DENDRITIC CELL; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; REBOUND; REMISSION; TRANSCRIPTION TERMINATION; VACCINATION; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 78649974978     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-13-S3-I1     Document Type: Conference Paper

References (35)

1. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. F Maldarelli S Palmer MS King A Wiegand MA Polis J Mican JA Kovacs RT Davey D Rock-Kress R Dewar S Liu JA Metcalf C Rehm SC Brun GJ Hanna DJ Kempf JM Coffin JW Mellors, PLoS Pathog 2007 3 4 46 10.1371/journal.ppat. 0030046 17411338
2. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Neuhaus DR Jacobs Jr JV Baker A Calmy D Duprez A La Rosa LH Kuller SL Pett M Ristola MJ Ross MG Shlipak R Tracy JD Neaton, J Infect Dis 2010 201 12 1788 1795 10.1086/652749 20446848
3. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. LH Kuller R Tracy W Belloso S De Wit F Drummond HC Lane B Ledergerber J Lundgren J Neuhaus D Nixon NI Paton JD Neaton INSIGHT SMART Study Group, PLoS Med 2008 5 10 203 10.1371/journal.pmed.0050203 18942885
4. Effect of Raltegravir-containing Intensification on HIV Burden and T Cell Activation in the Gut of HIV+ Adults on Suppressive ART. S Yukl A Shergill S Gianella A Choi V Girling M Downing H Lampiris H Guenthard J Wong D Havlir the PLUS Study Group, 17th Conference on Retroviruses and Opportunistic Infections San Francisco, USA 2010 Paper #279
5. Immune reconstitution in the sigmoid colon after long-term HIV therapy. PM Sheth D Chege LY Shin S Huibner FY Yue M Loutfy R Halpenny D Persad C Kovacs TW Chun G Kandel M Ostrowski R Kaul, Mucosal Immunol 2008 1 5 382 388 10.1038/mi.2008.23 19079202
6. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. MJ Buzán M Massanella JM Llibre A Esteve V Dahl MC Puertas JM Gatell P Domingo R Paredes M Sharkey S Palmer M Stevenson B Clotet J Blanco J Martinez-Picado, Nat Med 2010 16 4 460 465 10.1038/nm.2111 20228817
7. Raltegravir Intensification in Antiretroviral-treated Patients Exhibiting a Suboptimal CD4+ T Cell Response. H Hatano T Hayes V Dahl E Sinclair T-H Lee P Hunt S Palmer M Busch B Shacklett S Deeks, 17th Conference on Retroviruses and Opportunistic Infections San Francisco, USA 2010 Paper #101LB
8. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. JB Dinoso SY Kim AM Wiegand SE Palmer SJ Gange L Cranmer A O'Shea M Callender A Spivak T Brennan MF Kearney MA Proschan JM Mican CA Rehm JM Coffin JW Mellors RF Siliciano F Maldarelli, Proc Natl Acad Sci USA 2009 106 23 9403 9408 10.1073/pnas.0903107106 19470482
9. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. D McMahon J Jones A Wiegand SJ Gange M Kearney S Palmer S McNulty JA Metcalf E Acosta C Rehm JM Coffin JW Mellors F Maldarelli, Clin Infect Dis 2010 50 6 912 919 10.1086/650749 20156060
10. T Cell Senescence and T Cell Activation Predict Carotid Atherosclerosis in HIV-infected Women. R Kaplan E Sinclair A Landay N Lurain S Gange R Sharrett N Xue P Hunt H Hodis S Deeks, 17th Conference on Retroviruses and Opportunistic Infections San Francisco, USA 2010 Paper #709
11. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. N Chomont M El-Far P Ancuta L Trautmann FA Procopio B Yassine-Diab G Boucher MR Boulassel G Ghattas JM Brenchley TW Schacker BJ Hill DC Douek JP Routy EK Haddad RP Sékaly, Nat Med 2009 15 8 893 900 10.1038/nm.1972 19543283
12. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. TW Chun DC Nickle JS Justement D Large A Semerjian ME Curlin MA O'Shea CW Hallahan M Daucher DJ Ward S Moir JI Mullins C Kovacs AS Fauci, J Clin Invest 2005 115 11 3250 3255 10.1172/JCI26197 16276421
13. CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV-negative and ART-suppressed HIV-positive patients: implications for HIV persistence in the gut [Abstract]. S Yukl E Sinclair L Epling Q Li A Shergill K McQuaid L Duan B Hare H Lampiris A Haase D Havlir J Wong, Journal of the International AIDS Society 2010 13 Suppl 4 1
14. Most HIV DNA in PBMC is present in non-gut homing, resting memory CD4+ T cells with a 7-CD38-CD127 high phenotype [Abstract]. KK Koelsch Y Xu M Bailey K McBride N Seddiki K Suzuki J Murray DA Cooper AD Kelleher J Zaunders, Journal of the International AIDS Society 2010 13 Suppl 4 2
15. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. K Takahashi SL Wesselingh DE Griffin JC McArthur RT Johnson JD Glass, Ann Neurol 1996 39 6 705 711 10.1002/ana.410390606 8651642
16. Where are macrophage-tropic viruses? [Abstract]. G Schnell S Joseph S Spudich R Price R Swanstrom, Journal of the International AIDS Society 2010 13 Suppl 4 3
17. Novel pathways of transcriptional and post-transcriptional regulation of post-integrative HIV-1 latency [Abstract]. A Marcello A Kula M Dieudonne A Knezevich P Maiuri, Journal of the International AIDS Society 2010 13 Suppl 4 4
18. The cellular cofactor CTIP2 is a key regulator of HIV-1 latency [Abstract]. T Cherrier C Marban C Schwartz L Redel C Van Lint O Rohr, XVIII International AIDS Conference Vienna, Austria 2010 TUPE0004
19. HIV-1 Tat complexes reveal subunit composition of active P-TEFb and stable association with 7SKsnRNP [Abstract]. B Sobhian N Laguette A Yatim M Nakamura Y Levy R Kiernan M Benkirane, Journal of the International AIDS Society 2010 13 Suppl 4 5
20. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. G Hütter D Nowak M Mossner S Ganepola A Müssig K Allers T Schneider J Hofmann C Kücherer O Blau IW Blau WK Hofmann E Thiel, N Engl J Med 2009 360 7 692 698 10.1056/NEJMoa0802905 19213682
21. Homeostatic proliferation of memory T cells and expansion of the HIV-1 latent reservoir [Abstract]. A Bosque V Planelles, Journal of the International AIDS Society 2010 13 Suppl 4 6
22. Myeloid dendritic cells induce HIV-1 latency in non-proliferating CD4+ T cells [Abstract]. VA Evans S Saleh EK Haddad PU Cameron R-P Sekaly SR Lewin, Journal of the International AIDS Society 2010 13 Suppl 4 7
23. Common genetic variation and the control of HIV-1 in humans. J Fellay KV Shianna S Colombo B Ledergerber ET Cirulli TJ Urban K Zhang CE Gumbs JP Smith A Castagna A Cozzi-lepri A De Luca P Easterborrk HF Günthard S Mallal C Mussini J Dalmau J Martinez-Picado JM Miro N Obel SM Wolinsky JJ Martinson R Detels JB Margolick LP Jacobson P Descombes SE Antonarakis JS Beckmann JS OBrien NL Letvin AJ McMichael BF Haynes M Carrington S Feng A Telenti DB Goldstein NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI), PLoS Genet 2009 5 12 1000791 10.1371/journal.pgen.1000791 20041166
24. Tetherin restricts direct cell-cell viral transfer and transmission of HIV-1 [Abstract]. B Kuhl R Sloan D Donahue T Bar-Magen C Liang M Wainberg, Journal of the International AIDS Society 2010 13 Suppl 4 8
25. The role of the ubiquitin-proteasome pathway in rhTRIM5 restriction of HIV-1 [Abstract]. C Danielson T Hope, Journal of the International AIDS Society 2010 13 Suppl 4 9
26. LEDGF/p75 is critical but not essential for multiple round HIV-1 replication [Abstract]. RLG Schrijvers J De Rijck R Gijsbers K Ronen FD Bushman Z Debyser, Journal of the International AIDS Society 2010 13 Suppl 4 10
27. Changes in CD4+ cells' miRNA expression following exposure to HIV-1 [Abstract]. F Bignami E Pilotti L Bertoncelli P Ronzi M Gulli N Marmiroli G Magnani M Pinti C Mussini L Lopalco R Ruotolo M Galli A Cossarizza C Casoli, Journal of the International AIDS Society 2010 13 Suppl 4 11
28. Benito JM: Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia [Abstract]. C Garrido N Rallán N Zahonero M de la O Lápez V Soriano C de Mendoza JM Benito, Journal of the International AIDS Society 2010 13 Suppl 4 12
29. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. M Melek JM Jones MH O'Dea G Pais TR Burke Jr Y Pommier N Neamati M Gellert, Proc Natl Acad Sci USA 2002 99 1 134 137 10.1073/pnas.012610699 11756686
30. Effect of 24 weeks of intensification with a CCR5-antagonist on the decay of the HIV-1 latent reservoir [Abstract]. L Díaz C Gutiérrez C Page R Lorente B Hernndez-Novoa A Vallejo E Domínguez M Abad N Madrid A Moreno MJ Pérez-Elías R Rubio MA Mũoz-Fernndez S Moreno, Journal of the International AIDS Society 2010 13 Suppl 4 13
31. Purging the HIV-1 reservoir through the disruption of the PD-1 pathway [Abstract]. S DaFonseca N Chomont M El Far R Boulassel J Routy R Sékaly, Journal of the International AIDS Society 2010 13 Suppl 4 15
32. Measurements of total and integrated HIV DNA demonstrate sporadic blips of unintegrated HIV DNA in HIV-positive patients on HAART [Abstract]. A Mexas E Graf L Agosto JJ Yu M Pace M Liszewski S Migueles M Connors U O'Doherty, Journal of the International AIDS Society 2010 13 Suppl 4 16
33. Epigenetic drug Gar1041 in combination with antiretroviral therapy transiently reduces the proviral DNA reservoir in SIVmac251-infected macaques [Abstract]. MG Lewis S Norelli N Chomont S De Fonseca M Sgarbanti M Collins B Chirullo J Yalley-Ogunro J Greenhouse AT Palamara E Garaci A Savarino, Journal of the International AIDS Society 2010 13 Suppl 4 14
34. Survival of persons with and without HIV infection in Denmark, 1995-2005. N Lohse AB Hansen G Pedersen G Kronborg J Gerstoft HT Sørensen M Vaeth N Obel, Ann Intern Med 2007 146 2 87 95 17227932
35. The price of innovation: new estimates of drug development costs. JA DiMasi RW Hansen HG Grabowski, Journal of Health Economics 2003 22 151 185 10.1016/S0167-6296(02)00126-1 12606142